诺拉德林剂量切断以表征心血管衰竭的严重程度:基于数据的开发和外部验证
Anssi Pölkki1, Pirkka T Pekkarinen2, Benjamin Hess3
1Department of Anaesthesiology and Intensive Care, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland.
Acta anaesthesiologica Scandinavica
|August 30, 2024
概括
确定明确的诺拉德林 (诺拉上腺素) 剂量范围对于评估心血管衰竭严重程度至关重要. 这项研究确定了0.2和0.4μg/kg/min的切割值,以定义低剂量,中剂量和高剂量,与增加的医院死亡率相关.
科学领域:
- 关键护理医学 关键护理医学
- 心血管生理学心血管生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管压缩剂剂量是心血管衰竭严重程度的关键指标.
- 血管压缩剂剂量缺乏标准化范围使患者管理复杂化.
- 诺拉丁上腺素 (norepinephrine) 是重症监护机构中主要的血管压缩剂.
研究的目的:
- 为了建立一个统计学上合理的和实际的切断对诺拉丁上腺素 (诺上腺素) 的剂量.
- 定义低剂量,中剂量和高剂量类别的诺亚上腺素.
- 为了将这些剂量范围与医院死亡率联系起来.
主要方法:
- 采用芬兰和美国eICU数据库数据的双国注册表研究.
- 在ICU入院后24小时内,对最高的诺亚上腺素剂量进行分析.
- 应用Contal和O'Quigley方法与日志等级统计学来确定切断值.
主要成果:
- 在noradrenaline剂量范围内,确定了0.2和0.4μg/kg/min的切割值.
- 定义的范围:低 (<0.2),中等 (0.2-0.4) 和高 (>0.4μg/kg/min).
- 在开发和验证队伍中,与不断升级的诺亚上腺素剂量相比,医院死亡率显著增加.
结论:
- 最高的诺亚上腺素剂量有效量化了循环衰竭的严重程度.
- 建议的0.2和0.4μg/kg/min的切割值适用于分类诺亚上腺素剂量.
- 这些定义的范围有助于评估心血管支持水平和患者的结果.
相关概念视频
01:30Adrenergic Agonists: Therapeutic Uses
752
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
752
01:11Renal Failure: Dose Adjustments
69
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
69
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:16Antianginal Drugs: Nitrates and β-Blockers
547
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
547
01:31Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K